News headlines about Cynosure (NASDAQ:CYNO) have been trending somewhat positive this week, AlphaOne Sentiment reports. The research firm, a subsidiary of Accern, ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cynosure earned a news sentiment score of 0.02 on AlphaOne’s scale. AlphaOne also gave press coverage about the medical equipment provider an impact score of 65 out of 100, indicating that recent press coverage is somewhat likely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have impacted AlphaOne’s rankings:
Cynosure (NASDAQ:CYNO) remained flat at $66.00 on Friday. The firm has a 50 day moving average price of $62.47 and a 200-day moving average price of $50.89. Cynosure has a one year low of $39.90 and a one year high of $66.65.
Cynosure (NASDAQ:CYNO) last posted its quarterly earnings data on Tuesday, February 7th. The medical equipment provider reported $0.44 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.03. The firm earned $122.10 million during the quarter, compared to analysts’ expectations of $119.97 million. Cynosure had a return on equity of 6.86% and a net margin of 3.56%. The business’s quarterly revenue was up 19.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.42 EPS. On average, equities analysts expect that Cynosure will post $1.59 EPS for the current fiscal year.
CYNO has been the topic of several analyst reports. Northcoast Research downgraded Cynosure from a “buy” rating to a “sell” rating and set a $40.00 target price on the stock. in a report on Friday, January 6th. Northland Securities set a $60.00 target price on Cynosure and gave the stock a “buy” rating in a report on Monday, January 23rd. Zacks Investment Research downgraded Cynosure from a “hold” rating to a “sell” rating in a report on Monday, January 9th. Aegis reissued a “buy” rating and issued a $60.00 target price on shares of Cynosure in a report on Tuesday, January 24th. Finally, Maxim Group downgraded Cynosure from a “buy” rating to a “hold” rating and set a $66.00 target price on the stock. in a report on Tuesday, February 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. Cynosure currently has an average rating of “Hold” and an average target price of $58.63.
Cynosure Company Profile
Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.